[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graft-versus-host-disease-gvhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graft-versus-host-disease-gvhd":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,73,103,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100563352","phase-3-a-study-of-tacrolimusmethotrexateruxolitinib-versus-post-transplant-cyclophosphamidetacrolimusmycophenolate-mofetil-in-non-myeloablativereduced-intensity-conditioning-allogeneic-peripheral-blood-stem-cell-transplantation-bmt-ctn-2203-100563352",false,"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","A Randomized, Multicenter, Phase III Trial of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation","Inclusion Criteria:\n\n* Age 18.0 years or older at the time of enrollment.\n* Participants undergoing allogeneic HCT for one of the following indications:\n\n  * Acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 5% blasts in the bone marrow. Therapy related myeloid neoplasms are allowed.\n  * Myelodysplasia\u002Fchronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \\\u003C 5% versus 5-10% blasts in this disease). Therapy related myeloid neoplasms are allowed.\n  * Lymphoma \\[follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma\\].\n* Planned NMA\u002Freduced intensity conditioning regimen.\n* Participants must have a related or unrelated PBSC donor as follows:\n\n  * Sibling donor must be a 6\u002F6 match for HLA-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation. HLA-matched parents and children may be used as donors.\n  * Unrelated donor must be a 7\u002F8 or 8\u002F8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and meet NMDP criteria for donation.\n  * Donor selection must comply with 21 CFR 1271.\n* Cardiac function: Left ventricular ejection fraction at least 45%.\n* Estimated glomerular filtration rate greater than 60 ml\u002Fmin\u002F1.73 m2 using the 2021 CKD-EPI formula Note: For eligibility, GFR by 2021 CKD-EPI is required. A baseline creatinine clearance by Cockcroft-Gault should be done to establish baseline CrCl for ruxolitinib dosing.\n* Pulmonary function: DLCO corrected for hemoglobin at least 40% and FEV1 predicted at least 50%.\n* Liver function: AST\u002FALT \\\u003C 3x ULN; Total bilirubin \\\u003C 2 mg\u002FdL excluding Gilbert's syndrome or hemolysis.\n* Karnofsky Performance Score of at least 60%.\n* Female participants (unless postmenopausal for at least one year before the screening visit, or surgically sterilized), agree to practice two effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 15 months post-transplant. Fertility preservation methods will be left to institutional standards.\n* Male participants (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 15 months post-transplant.\n* Plans for the use of targeted small molecule inhibitor post-transplant maintenance therapy must be disclosed upon enrollment and must be used irrespective of the outcome of the randomization. Planned use of investigational maintenance agents is not permitted. Planned hypomethylating agents as maintenance therapy is not permitted.\n* Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\n* Prior allogeneic transplant.\n* Active CNS involvement by malignant cells.\n* Participants with secondary AML arising from myeloproliferative neoplasms or secondary AML arising from overlap syndromes, including CMML and MDS\u002FMPN syndromes; participants with secondary AML arising from myelodysplastic neoplasm are eligible.\n* Participants with primary, post-Essential Thrombocythemia (post-ET) and post-Polycythemia Vera (post-PV) myelofibrosis.\n* Participants with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.\n* Active or inadequately treated latent infection with Mycobacterium tuberculosis (i.e., TB).\n* Presence of clinically significant fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.\n* Participants seropositive for human immunodeficiency virus (HIV) with detectable viral load. HIV+ participants with an undetectable viral load on antiviral therapy are eligible.\n* Evidence of uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV). The study allows:\n\n  * Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis to prevent potential HBV reactivation.\n  * Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.\n* Arterial or venous thrombosis including DVT, PE, stroke, and myocardial infarction within six (6) months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia. Catheter-associated DVT is not exclusionary.\n* Female participants who are pregnant (as per institutional practice) or lactating.\n* Participants with a serious medical or psychiatric illness likely to interfere with participation in this clinical study.\n* Participants with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \\\u003C 5 years previously must be reviewed and approved by the Protocol Officer or Chairs.\n* Planned use of ATG or alemtuzumab in conditioning regimen.\n* Planned use of prophylactic donor leukocyte infusions.\n* Prior use of ruxolitinib.\n* Prior use of immune checkpoint inhibitors (i.e., PD1, PDL1, CTLA4 modulators) within six (6) months prior to conditioning.\n* For participants with 7\u002F8 HLA-matched donors:\n\n  * Donor specific antibodies (DSAs) directed at the mismatched donor allele.\n  * Any use of desensitization protocols.\n* Treatment with any other Investigational Medicinal Product (IMP) is not allowed while on study treatment. An IMP is defined as medications without any known FDA or EMA approved indications.","ALL","18 Years",{"count":19,"type":20},572,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to assess Tacrolimus\u002FMethotrexate\u002FRuxolitinib versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation",[26],"Graft-versus-host Disease (GVHD)",[26,28,29,30,31],"Chronic GvHD (cGvHD)","steroid-refractory","ruxolitinib","Janus kinase inhibitor","RECRUITING","2026-05-19",{"date":35,"type":36},"2026-05-20","ACTUAL",{"date":38,"type":36},"2025-04-02",{"date":40,"type":20},"2031-01-17",{"name":42,"class":43},"Incyte Corporation","INDUSTRY",30,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100587300","phase-2-allogeneic-hsct-with-low-dose-post-transplant-cyclophosphamide-for-gvhd-prevention-100587300","NCT06926595","Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention","Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies","GVHD-PTCy","Inclusion Criteria:\n\n* Age 18 or older at the time of study enrollment.\n* Patients with acute leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, mixed phenotype acute leukemia) or chronic myeloid leukemia with no circulating blasts and less than 5% blasts in the bone marrow.\n\nFlow cytometric, polymerase chain reaction (PCR) or next generation sequencing (NGS) detected measurable residual disease is permitted.\n\n* Patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia with no circulating blasts and less than 10% blasts in the bone marrow (exception allowed due to lack of difference in outcomes with \\\u003C5% vs 5-10% blasts in this disease).\n* Patients with secondary acute myeloid leukemia progressing from pre-existing myelodysplastic syndrome, myeloproliferative disease (MPN), or MDS\u002FMPN overlap syndrome.\n* Patients with relapsed or refractory chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma who are indicated for allogeneic stem cell transplantation.\n* Patients with lymphoma who are indicated for allogeneic stem cell transplantation, including follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma (including primary mediastinal B cell lymphoma), mantle cell lymphoma, peripheral T cell lymphomas, and Richter's transformation.\n* Planned reduced intensity or non-myeloablative conditioning regimen.\n* Patients must have a related or unrelated peripheral blood stem cell donor as follows:\n\nSibling donor must be at least haploidentical using high resolution DNA-based HLA typing.\n\nChildren or parent donor must be at least haploidentical using high resolution DNA-based HLA typing. Children donors must be at least 18 years of age at the time of evaluation.\n\nUnrelated donors must be a 7\u002F8 or 8\u002F8 match at HLA-A, B, C, and DRB1 at high resolution using DNA based typing.\n\n* Cardiac function: must demonstrate at ejection fraction of at least 40%.\n* Pulmonary function: must have FEV1 of at least 50% predicted, and DLCO corrected for hemoglobin of at least 40% predicted.\n* Karnofsky performance status at least 70%.\n* Women of childbearing potential (WOCP), defined as not surgically sterile (hysterectomy, tubal ligation, or oophorectomy) or at least 1 year postmenopausal, must have a negative serum pregnancy test before conditioning regimen.\n* Female patients (unless post-menopausal or surgically sterilized) must agree to practice two effective methods of contraception simultaneously or agree to completely abstain from heterosexual intercourse from the time of signing informed consent through 12 months post-transplant.\n* Male patients (even if surgically sterilized) who are partners of women of childbearing potential must agree to practice effective barrier contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant.\n\nExclusion Criteria:\n\n* Prior allogeneic stem cell transplant.\n* Active central nervous system (CNS) involvement by malignant cells.\n* Uncontrolled bacterial, viral, or fungal infections (currently taking medication with progression or no clinical improvement).\n* Seropositive for human immunodeficiency virus (HIV) with detectable viral load, hepatitis B virus (HBV) or hepatitis C virus (HCV) with detectable viral load. Hepatitis B surface antibody positive due to vaccination or natural immunity are permitted. Patients previously treated for HCV and considered to be in sustained virologic remission (SVR) are allowed.\n* Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III-IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.\n* Pregnant or lactating female patients (unless feeding via formula). Women of childbearing potential (WOCBP) are required to have a negative serum or urine pregnancy test prior to conditioning regimen.\n* Serious medical or psychiatric illness likely to interfere with participation in the study.\n* Use of investigational agents.\n* Haploidentical related recipient who are positive for DSA ≥ 5000 MFI by solid phase microarray method (Luminex).\n* Any patient with steroid dose more than 10 mg\u002Fday within a week of registration.\n* Autoimmune disorder requiring any active immunosuppression therapy.",{"count":54,"type":20},41,[56],"PHASE2","This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg\u002Fkg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myeloablative conditioning. The study will focus on matched sibling, matched unrelated, and haploidentical peripheral blood stem cell donors. The primary endpoint is 1-year GVHD-Free Relapse-Free Survival (GRFS). The study seeks to determine if low-dose PTCy offers similar outcomes as higher doses, with potentially reduced toxicity.",[59,60,61],"Graft-versus-Host Disease (GVHD)","Hematologic Malignancies","Allogeneic Stem Cell Transplantation","2026-03-30",{"date":64,"type":36},"2026-04-03",{"date":66,"type":36},"2026-03-09",{"date":68,"type":20},"2031-11-01",{"name":70,"class":71},"Milton S. Hershey Medical Center","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100608145","early-phase-1-vitamin-c-with-steroids-for-gastrointestinal-gvhd-100608145","NCT07197749","Vitamin C With Steroids for Gastrointestinal GVHD","Administration of Vitamin C (Ascorbic Acid) With Steroids for First Line Therapy of Gastrointestinal GVHD","Inclusion Criteria:\n\n1. Patients 5 years of age or older at time of enrollment.\n2. Patients experiencing their initial presentation of stage 2 or greater acute LGI GVHD (with or without other organ involvement) or stage 1 LGI + skin aGVHD requiring systemic therapy after allogeneic transplant for any malignant or non-malignant indication using any graft\u002Fdonor source or conditioning intensity.\n3. KPS ≥70%\n4. Patients should not have received systemic immune suppressive therapy for treatment of active GVHD except for a maximum of 72 hours of steroid therapy (with or without ruxolitinib) prior to enrollment. Topical skin and GI corticosteroids (such as budesonide and oral beclomethasone diproprionate) are allowed.\n5. Informed Consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nExclusion Criteria:\n\n1. Relapsed, progressing or persistent malignancy or evidence of minimal residual disease (MRD) requiring withdrawal of systemic immune suppression.\n2. Patients with acute GVHD developing after administration of a donor lymphocyte infusion (DLI) for relapse\u002Fprogression of disease.\n3. Patients with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms\n4. Known or suspected hypersensitivity to vitamin C.\n5. De novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment.\n6. Patients receiving other drugs for the treatment of GVHD except as noted above. GVHD prophylaxis agents (e.g., calcineurin inhibitors) may be continued at local Investigator's discretion.\n7. Patients on renal replacement therapy.\n8. Patients requiring continuous supplemental oxygen \\> 2L\u002Fmin to maintain peripheral O2 saturation \\[SpO2\\] \\> 90%.\n9. Patients with active hepatic sinusoidal obstructive syndrome (SOS) and\u002For clinical evidence of impaired hepatic function (ascites or encephalopathy related to liver disease.\n10. Patients receiving systemic corticosteroids (CS) for any indication within 7 days before enrollment, except the following:\n\n    1. Corticosteroids administered as premedication for supportive care (such as before transfusion of blood products or before intravenous medications to prevent infusion reactions, fever, etc.).\n    2. If steroid therapy has been administered for treatment of a non-GVHD related condition and tapered to \\\u003C 0.6 mg\u002Fkg\u002Fday prednisone (0.5 mg\u002Fkg\u002Fday methylprednisolone) for 7 or more days prior to enrollment.\n11. History of G6PD deficiency, sickle cell disease or hemochromatosis.\n12. History of oxalate kidney stones.\n13. Patients unlikely to be adherent to study specific assessments at the transplant center.","5 Years",{"count":82,"type":20},35,[84],"EARLY_PHASE1","After a transplant from another donor, one risk is graft versus host disease (GVHD) that happens because of differences between the donated cells (graft) and the patient's body cells (host). The new cells from the donor might see the body's cells as different and attack them. GVHD can be very serious and cause death. The standard first treatment for GVHD is corticosteroids but not all patients respond and in cases where they don't, they need to go onto other treatments that may or may not be effective. In addition, when GHVD involves the gut it can damage the cells of the gastrointestinal track causing long term problems such as abdominal pain and bowel disturbance. In laboratory studies giving a vitamin C has been able to protect the gastrointestinal cells and help them recover. In this trial the investigators would like to see if vitamin C can do the same thing when given with steroids in patients with GVHD.\n\nThe standard first treatment for acute GVHD is corticosteroids but not all patients respond and in cases where they don't, they need to go onto other treatments that may or may not be effective. In addition, when GHVD involves the gut it can damage the cells of the gastrointestinal track causing long term problems such as abdominal pain and bowel disturbance. In the laboratory vitamin C has been able to protect gut stem cells and help them recover and the investigators would like to learn if this happens in people too.\n\nVitamin C is a readily available supplement. Vitamin C has NOT been approved by the FDA for the treatment of acute GVHD.",[87,88],"Graft-versus-host-disease (GVHD)","Gastrointestinal",[90,91,92,88],"Graft-Versus-Host-Disease","GVHD","Vitamin C","NOT_YET_RECRUITING","2026-03-03",{"date":96,"type":36},"2026-03-04",{"date":98,"type":20},"2026-06",{"date":100,"type":20},"2029-10",{"name":102,"class":71},"Baylor College of Medicine",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":72},"100577507","phase-2-optimizing-gvhd-prophylaxis-after-allogeneic-hematopoietic-cell-transplantation-100577507","NCT06799195","Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial","PTCYGVHD","Inclusion criteria:\n\n* Adults aged 60 years or older\n* Diagnosis of a hematological malignancy or other serious hematological disorder that requires an allogeneic hematopoietic cell transplantation\n* Planned to receive any reduced-intensity conditioning regimen (any graft source is acceptable) and availability of human leukocyte antigen (HLA)-matched donor at HLA loci A, B, C, and HLA-DR beta chain antigen (DRB1)\n* Karnofsky Performance Status (KPS) of 70% or higher.\n\nExclusion criteria:\n\n* Previous history of one or more prior allogeneic stem cell transplants (i.e., second or third allogeneic transplant)\n* Planned use of high doses of cyclophosphamide (e.g., a total cyclophosphamide dose of approximately 50 mg\u002Fkg or more) as part of the conditioning regimen prior to allogeneic stem cell transplant. A lower dose of cyclophosphamide (e.g., fludarabine, cyclophosphamide, and low-dose total body irradiation regimen that uses 2 doses of cyclophosphamide at 14.5 mg\u002Fkg) is acceptable.\n* Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism.\n* Diagnosis of myelofibrosis\n* Creatinine clearance less than 40 mL\u002Fmin\u002F1.73 m², which may increase the risk of hemorrhagic cystitis with post-transplant cyclophosphamide (PTCy)\n* Systolic cardiac dysfunction with an ejection fraction of less than 45%.\n* Use of a haploidentical or mismatched donor.\n* Any other condition judged by the physician to increase the risk of toxicities associated with PTCy.","60 Years",{"count":113,"type":20},126,[56],"This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.",[117,59],"Hematological Malignancies",[119,120,121,122,123,124],"Allogeneic Hematopoietic Stem Cell Transplantation","GVHD Prophylaxis","Sirolimus","Mycophenolate Mofetil (MMF)","Health-Related Quality of Life (HRQoL)","Randomized Controlled Trial","2025-12-08",{"date":127,"type":36},"2025-12-15",{"date":129,"type":36},"2025-06-23",{"date":131,"type":20},"2031-11",{"name":133,"class":71},"University of Nebraska",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":72},"100564250","phase-2-dapagliflozin-in-allo-hct-for-agvhd-100564250","NCT06626737","Dapagliflozin in Allo-HCT for aGVHD","Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study","DAPALAG-01","Inclusion Criteria:\n\n* Age 18 to 65 years old.\n* Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor.\n* Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis base on cyclosporin A and methotrexate.\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n* Patients with prior use of Dapagliflozin or other hypoglycemic medications may switch to Dapagliflozin, contingent upon the treating physician's assessment of contraindications, will be eligible.\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures.\n\nExclusion Criteria:\n\n* With other malignancies.\n* With a previous history of autologous hematopoietic cell transplantation, allo-HCT or chimeric antigen receptor T-cell therapy.\n* With a history of allergies to Dapagliflozin.\n* With type 1 diabetes or a history of ketoacidosis.\n* With a history of recurrent urinary tract infections.\n* With severe organ dysfunction.\n* With active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection.\n* In pregnancy or lactation period.\n* With any conditions not suitable for the trial (investigators' decision).","65 Years",{"count":144,"type":20},72,[56],"The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.",[26],[149,150,151],"Dapagliflozin","Graft-versus-host disease","Allogeneic hematopoietic cell transplantation","2025-06-02",{"date":154,"type":36},"2025-06-05",{"date":156,"type":36},"2025-04-26",{"date":158,"type":20},"2026-12-31",{"name":160,"class":71},"The First Affiliated Hospital of Soochow University","Graft Versus Host Disease (GVHD)"]